

### 9th Annual

# CAR-TCR Summit

**Engineering a Disease-Free World** 

September 17-20, 2024 I Boston, MA

**Achieve Safe & Successful Clinical Translation Across Oncology & Autoimmune Diseases with Automated & Streamlined Manufacturing** Processes, to Reinvigorate Investment within the Cell Therapy Community

120+ World-Class Speakers, Including:



**Pascal Touchon** President & Chief **Executive Officer** Atara Biotherapeutics



**David Sourdive** Co-Founder & Executive Vice President, CMC & Manufacturing





**Amy Emmert** Executive Director, Cell Therapy Facility Dana Farber Cance



Mvthili Koneru Chief Medical Officer **Legend Biotech** 



Vicki Plaks Global Head of Cell Therapy, Translational Research



Elisa Kieback Co-Founder & Chief **Technology Officer** 



Chief Technology



Carl June Professor in Immunotherapy, Director, Center for Cellular **Immunotherapies** 

**Proud to Partner With:** 

**Lead Partner** 



**Expertise Partners** 













**WELCOME** 

CONTENTS

**REGISTER BY APRIL 26** 

**& SAVE UP** TO \$1,500!

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

**CONFERENCE DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

> **PARTNER** WITH US

REGISTER

NOW

www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com





hansonwade

### Welcome to the 9th CAR-TCR Summit

Despite safety concerns and high investment standards, we've seen CAR-T move to earlier-line treatments, billion dollar partnerships, notable clinical advances in glioblastoma and autoimmunity, and further commercial approvals are imminent. 2024 is the year to continue this progression to further investment, accessibility and durability; exhibit clinical benefit, and improve cost-efficiency.

The 9th CAR-TCR Summit returns as the industry's premier event of the year. This is your team's one-stop-shop to exchange cutting-edge scientific data, join solution-led discussions to overcome development bottlenecks, and foster new collaborations to advance clinical and commercial development.

Committed to ensuring this important learning and networking event is accessible, the newly refined 2-day conference will provide insight on the hottest advances across Discovery, Translation, Clinical Development, Early-Stage Manufacturing, Late-Stage Manufacturing, Analytical Development and Supply & Clinical Operations, to upskill entire teams and streamline processes from bench to bedside.

New for this year, we are thrilled to announce the Carl June CAR-TCR Travel Fund Award. Here, we will be working with Dr. Carl June to award selected academics free attendance and travel support to the meeting, ensuring industry and academic collaboration even in financially trying times.

The diverse program showcases experts across innovation, clinical and commercial stages, including Arsenal Bio, BMS, Cartesian Therapeutics, Cellectis, Legend Biotech, Novartis and UPenn, providing insights to unlock unmatched durability, boost cost-efficiency and transform clinical outcome. Whether you are a C-Level decision maker, or a scientist working on the front line, this meeting is for you.

Don't miss the community's most comprehensive meeting of the year which strives to develop CAR and TCR therapies that are potent, targeted and durable, through a process that is closed, faster and cheaper.

Together, we will bring these life-changing therapies to the patients that need them.



## **Unmissable New Features:**

#### 2x Post-Conference Focus Days

#### **Tackling Solid Tumors:**

As the tumor microenvironment remains a key barrier to efficacy in solid tumors, collaborate to improve trafficking, enhance penetration, and optimize armoring and combination strategies to potentiate durability in hardto-treat indications.

#### **Automation & Manufacturing Technology:**

As automation and closed manufacturing systems unlock the potential to boost productivity, minimize error, and reduce costs, examine best-practice to implement and leverage technologies to reinvent production efficiencies.

#### **Carl June Travel Fund Award**

A new initiative open to academic labs to support their travel and attendance, benefit from engaging with the field, spark new collaborations and apply learnings to advance leading research, reviewed and presented by Dr. Carl June himself.

Submit your abstract through our website to be in with a chance of winning!

#### **Investment & Strategy Bootcamp**

Gain insights into the decision-making process of VCs, investors and big pharma search and evaluation teams to support your partnering and funding strategy, while reflecting on market access and profitability to guarantee commercial success when the time comes.

### **New Companies on the Speaker Faculty:**















**CONTENTS** 

**REGISTER** 

**BY APRIL 26** 

**& SAVE UP** TO \$1,500!

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

**WHO WILL YOU** MEET?

PRE-**CONFERENCE** DAY

CONFERENCE **DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 





### A Sneak Peek at the 2024 Expert Speaker Faculty

CAR-TCR Summit

**REGISTER BY APRIL 26** 

**& SAVE UP** 

TO \$1,500!

**CONTENTS** 

**WELCOME** 

WHAT'S NEW?

**EXPERT** 

**SPEAKERS** 

MAP OUT YOUR **MEETING** 

**WHO WILL YOU** MEET?

PRE-**CONFERENCE** DAY

**CONFERENCE** 

**DAY ONE** 

**CONFERENCE** 

**DAY TWO** 

POST-

**CONFERENCE FOCUS DAY** 

**PARTNER** 

WITH US

September 17-20, 2024 I Boston, MA



**Patrick Halvey Director Clinical** Biomarker Development. Precision & Translational Medicine Affini-T Therapeutics



**Haixia Wang** Head of Analytical Development **Arsenal Bio** 



**Pascal Touchon** President & Chief **Executive Officer Atara Biotherapeutics** 



Marcella Goodnight Senior Director, MSAT **BioNTech** 



**Arun Pores Fernando** Director, Business Development, Search & Evaluation, Cell Therapy **Bristol Myers Squibb** 



**Chris Jewell** Chief Scientific Officer **Cartesian Therapeutics** 



**David Sourdive** Co-Founder & Executive Vice President, CMC & Manufacturing **Cellectis** 



Simon Bornschein Chief Executive Officer coding.bio



Alexandria Cogdill Executive Director & Head of Global Research & Technology Seach & Evaluation, External Innovation & Global Business Development **Daiichi Sankvo** 



**Amy Emmert** Executive Director, Cell Therapy Facility **Dana Farber Cancer** Institute



**Matthias Scroff** Chief Executive Officer **Inceptor Bio** 



Vicki Plaks Global Head of Cell Therapy, Translational Research Johnson & Johnson



Mythili Koneru Chief Medical Officer **Legend Biotech** 



Joseph Maguire Head, GMP Automation & Data Lyell Immunopharma



Sarah Hein Co-Founder & Chief **Executive Officer March Biosciences** 



Vice President, Head of Cell & Gene Global Value & Access **Novartis** 

hansonwade



**Fabio Fachin** Executive Director, Cell Therapy **Takeda** 



**Ganesh Mugundu** Head of Clinical & Quantitative Pharmacology, Cell Therapy **Takeda** 



Elisa Kieback Co-Founder & Chief Technology Officer **T-knife Therapeutics** 




**Justin McCue** Chief Technology Officer **TScan Therapeutics** 



Jill Goldstein Senior Associate **Vida Ventures** 

Presenter of the Carl June **CAR-TCR Travel Fund** Award:



**Carl June** Professor in Immunotherapy, Director, Center for Cellular Immunotherapies University of Pennsylvania

**REGISTER NOW** 



## Map Out Your CAR-TCR Summit Journey



**REGISTER BY APRIL 26** 

**& SAVE UP** TO \$1,500!

#### CONTENTS

**WELCOME** 

WHAT'S NEW?

**EXPERT** 

MAP OUT YOUR

WHO WILL YOU

PRE-DAY

CONFERENCE **DAY ONE** 

**CONFERENCE DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

**SPEAKERS** 

**MEETING** 

MEET?


CONFERENCE

### **PARTNER** WITH US



hansonwade

#### **DISCOVERY**





Who? Discovery, Pre-Clinical and R&D innovators



How? Explore autoimmune applications, in vivo cell therapies, non-viral engineering and novel target discovery

TRANSLATION

Who? Translational, Pharmacology and

How? Harness in vivo and in vitro data, and

uncover biomarkers to effectively translate safety

Biomarker Development teams

and efficacy in humans

Patient Outcome

What? Streamlining Clinical Transfer & Boosting

It can be hard to navigate a large agenda, so here's a breakdown of each track so you can find the most relevant content quickly and easily!



### SUPPLY CHAIN & CLINICAL OPERATIONS



What? Coordinating Fast & Efficient Delivery of Products to Patients



Who? Supply Chain, Logistics, Operations and Clinical Operations teams



How? Employ digitalization, mitigate risk to optimize patient scheduling, manage competition and facilitate geo-expansion

#### ANALYTICAL DEVELOPMENT



What? Developing Robust Bioassays for Compliance & Efficient Product Release



Who? Analytical, CMC, Quality, Regulatory and Assay Developers



How? Accelerate assay development for potency, characterization, purity and stability to ensure high product quality and regulatory compliance

#### **CLINICAL DEVELOPMENT**



What? Demonstrating Efficacy, Durability & Safety in Patients to Achieve Clinical Validation



Who? Clinical and Medical teams



How? Discover the latest clinical data across a range of approaches and indications

#### **EARLY-STAGE MANUFACTURING**



What? Establishing & Optimizing Process Development Platforms: Simple, Cheap & Fast



Who? Pre-Clinical and Early Clinical Manufacturing, Process Development and CMC



How? Transform CMC strategy, establish and optimize rapid process development and complex product manufacturing

#### LATE-STAGE MANUFACTURING



What? Mastering Scale-Up & Out to Facilitate Commercial Production



Who? Clinical Manufacturing, GMP, Quality, CMC, MSAT, Regulatory and Commercial teams



How? Maintain quality and comparability. decrease cost, and accelerate production at a large-scale through robust closed systems

## Who Will You Meet?

This is the only meeting where you'll meet the complete range of CAR-TCR drug developers, making it your one-stop-shop for networking, learning and vendor research. Audience includes:

- Autologous, allogeneic and in vivo experts
- Those targeting indications across heme, solid tumors and autoimmunity
- Those targeting cell types including αβΤ, γδΤ, NK, Macrophage, TIL and Treg
- Companies in development stages from discovery to commercial
- All seniorities spanning C-level to scientists
- Academics, small and large biotech, big pharma, investors and service providers

You and your team can meet and learn from other experts in your specific functions, including:



Discovery & R&D



Translation & Pharmacology



Pre-Clinical, Clinical & Commercial Development



Process Development, CMC & Manufacturing



Analytical Development, Quality & Regulatory



Supply Chain, Logistics & **Clinical Operations** 



**Business Development &** Strategy

### Facilitating your Connections

Explore our Unique Range of Networking Opportunities:



Badge scanning capabilities through the event app to collect all your business cards in one place





**Utilize One-on-One Partnering™**, the life sciences' leading networking event platform by Inova, a tool for managing and pre-scheduling one-on-one meetings



Coloured badge labels and structured networking to easily identify those working in similar functions





Small group discussions to dive deep into the challenges that matter to you and like-minded peers


Drinks Receptions: the best way to wind down with your peers with a glass in hand



Snapshot of Previous Attendees: 2seventybio?































www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com



in CAR-TCR Summit Series





**CONTENTS** 

**REGISTER** 

**BY APRIL 26** 

**& SAVE UP** TO \$1,500!

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

CONFERENCE **DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

> **PARTNER** WITH US

REGISTER

NOW

### Pre-Conference Day - Tuesday, September 17



September 17-20, 2024 I Boston, MA

Deep-Dive Workshop Day			CAR-TCR 101: The Fundamentals	Investment & Strategy Bootcamp	
	n an intimate environment to enakeaways for you and your tean		Whether you're in a junior role or a senior lead transferring into the field, join to gain a comprehensive background into cell therapies and their many types	Collaborate to understand the current funding environment and gain insights to safeguard cash runways and support progression	
Pre-Clinical Workshops	Clinical Workshops	Manufacturing Workshops	Fundamentals 101: Introducing Engineered Cell Immunotherapies	Safeguarding an Economically Enduring Future of Cell Therapies	
Workshop A  Mediating Targeted Cell	Workshop B Guaranteeing Clinical Safety	Workshop C Preparing Early to Streamline	Reviewing CARs, TCRs & TIL backgrounds, and next-generation approaches	Uncover investor's views on the current cell therapy field and future opportunity for a range of approaches	
Activation & Implementing Safety Switches to Reinvent Cell Therapy Safety	& Measuring Long-Term Benefit to Minimize Toxicities & Demonstrate Risk-Benefit Ratio	Commercial Readiness Across Manufacturing, Supply Chain & Product Release	Evaluating Cell Therapy Approaches to Strengthen Strategy & Understand Priorities  Dive into cell types and allogeneic approaches	Reaffirming Internal Strategy to Promote Corporate Success  Ensure cell therapy profitability and discuss market access strategies to prepare early for commercial success	
		Lunch E	Break & Networking		
Workshop D  Applying Artificial Intelligence (AI) & Machine Learning to Reimagine Cell Therapy Discovery & Product Optimization	Workshop E  Pursuing Clinical Trials in Autoimmunity to Expand Treatment Application & Increase Accessibility	Workshop F Overcoming Challenges of Harnessing Non-Viral Engineering in Manufacturing	Exploring Next Generation Advances to Turbocharge Future Cell Therapy Products Explore in vivo and autoimmune applications Engineering Beyond the CAR: Enhancing Efficacies & Safety	Survival of the Fittest: Securing Cash Runways to Support Progression  Distinguish platform capabilities in a competitive funding environment and discuss how to obtain industry partnerships	

Refreshment Break

#### **Driving Diversity in CAR-TCR Workshop**

Diversity in the Workplace: Ensuring diverse representation throughout the cell therapy space Diversity in Clinical Trials: Extending patient populations to include subgroups and minorities to ensure ethnic inclusion and reduce disparities

#### C-Level Think Tank (\*Invite Only)

An exclusive invite-only session providing an opportunity for top C-Level Executives to gather in a closed room setting to discuss the most pressing challenges facing the CAR-TCR field. Join to share thought leadership on how to drive efficacies, safety, cost efficiency and accessibility of cell therapies

Welcome Reception



www.car-tcr-summit.com Tel: +1 617 455 4188 Email: info@hansonwade.com in CAR-TCR Summit Series

methods and ensure smooth delivery





**REGISTER BY APRIL 26 & SAVE UP** TO \$1,500!

**CONTENTS** 

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-CONFERENCE DAY

CONFERENCE **DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

> **PARTNER** WITH US

**REGISTER** NOW

### Conference Day One - Wednesday, September 18



September 17-20, 2024 I Boston, MA

Check-In Open

**Opening Remarks** 

The Year in Focus: Diving into Progression & Remaining Opportunity

Industry Leaders Fireside Chat: Reviewing Success, Safety & Shortfalls of Cell Therapies Over the Year

**Industry Keynote Presentation** 

Morning Break & Networking

Discovery Track	Translation Track	Clinical Development Track	Early-Stage Manufacturing Track	Late -Stage Manufacturing Track	Analytical Development Track	Supply Chain & Clinical Operations Track
Shifting Focus to Autoimmune Applications to Open Patient Pool & Expand Cell Therapy Potential	Demonstrating Safety & Efficacy <i>In Vitro</i> & <i>In Vivo</i> to Streamline the Road to IND	Deep Diving into the Clinic: Spotlighting Safe, Effective & Durable Cell Therapies to Validate Patient Safety & Clinical Outcome	Establishing Optimal CMC Strategy & Process Development Platforms: Simple, Cheap & Fast	Streamlining Scale-Up Beyond Phase I to Cater to Increased Demand in a Cost-Efficient Manner	Reimagining Potency Assay Development to Facilitate Product Release	Employing Digitalization to Facilitate Operations, Tracking & Scheduling
Moving Beyond Lupus: Setting Up CAR-Ts for Success in Harder- to-Treat Autoimmune Indications	Driving Rapid Translation of CD70 Targeting CAR-NK Therapy from Discovery through to Clinical Development	Battling the Solid Tumor Microenvironment with an Armored Cell Therapy to Elicit a Safe & Beneficial Outcome	Developing a Novel Cost- Effective Manufacturing Process for Cord Blood Derived Allogeneic CAR- NKT Products	Maintaining Cost of Goods Throughout Scale- Up	Delving into Therapeutics' Mechanism of Action to Identify Relevant Critical Quality Attributes (CQAs)	Navigating Smooth Implementation of Digital IT Infrastructure Across the Supply Chain
Engineering Tregs with a CAR or TCR to Mediate Specific & Durable Autoimmune Disease Targeting	Pre-Clinical & IND- Enabling Assessment of the Efficacy & Safety of Solid Tumor-Targeted Integrated Circuit T-Cells	Clinical Experience with Allogeneic Cell Therapy in Multiple Sclerosis & Next Steps in Autoimmune Diseases	Manufacturing Customized, Enhanced Multiplexed TCR-T Cell Therapy Products Using Next Generation Non- Viral Vectors	Upholding Cell Viability at Larger Scale Production to Maintain Quality	Creating Robust & Standardized Assays to Measure Potency	Harnessing Digital Systems to Facilitate Chain of Identity & Custody

Lunch Break & Networking







#### **CONTENTS**

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

**CONFERENCE DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

> **PARTNER** WITH US



hansonwade

### Conference Day One - Wednesday, September 18



September 17-20, 2024 I Boston, MA

Discovery Track	Translation Track	Clinical Development Track	Early-Stage Manufacturing Track	Late-Stage Manufacturing Track	Analytical Development Track	Supply Chain & Clinical Operations Track
Leveraging Non-Viral Engineering to Improve Accuracy of Insertion or Deletion & Enhance Safety	Streamlining Forward & Reverse Translation to Maximize Safety & Clinical Outcome	Deep Diving into the Clinic: Spotlighting Safe, Effective & Durable Cell Therapies to Validate Patient Safety & Clinical Outcome	Reimagining Rapid Manufacturing to Shorten Turnaround While Retaining Quality	Mitigating Risk in Manufacturing to Improve Product Quality & Consistency	Tackling Variability to Progress Bioassay Development for Heterogeneous Cell Products	Redefining Clinical Operations to Progress Patient Standard of Care
Reinventing Engineering Specificity to Prevent Immunogenicity	Co-Engagement of CAR & Co-Receptors Enable T-Cells to Overcome Tumor Resistance Mechanisms	Analyzing the Risk of Secondary Malignancy After Commercial CAR-T Therapy: Demonstrating the Benefit	Simplifying Processes to Reduce Manufacturing Complexity	Maximizing the Potential of Electronic Systems to Mitigate Risk & Minimize Time to Patient Delivery	Coping with Product & Donor Variability to Build Robust Characterization Assays	Boosting Efficiency of Patient Scheduling to Decrease Vein-to-Vein Time
Advancing TCR-T Therapies: Non-Viral Engineering Strategies for Enhanced Scale-Out	Clinical Biomarker of Response to Ciltacabtagene Autoleucel in Patients with Relapse or Refractory Multiple Myeloma	ACTengine® IMA203 TCR-T: Unleashing the Potential of Targeting PRAME in Solid Tumors	Panel Discussion: Discussing Best Process Improvement Strategies to Accelerate Production	Integrating Manufacturing & Analytical Processes into a Single System to Create End-to-End Production Capabilities	Transforming Genetic Characterization to Advance Safety Testing for Complex Engineered Products	Mitigating Risk & Elevating Communication to Create a Patient Centric Experience

Afternoon Break & Networking

#### **Celebrating Academic Success & Identifying Future Progression**

Presentation of the Carl June CAR-TCR Travel Fund Award

Academic Leaders Fireside Chat: Cell Therapies from Then to Now: Celebrating Progress & Highlighting Future Potential

**Academic Keynote Presentation** 

**Drinks Reception** 



**REGISTER BY APRIL 26 & SAVE UP** TO \$1,500!

**CONTENTS** 

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-CONFERENCE DAY

CONFERENCE **DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 





### Conference Day Two - Thursday, September 19



September 17-20, 2024 I Boston, MA

**Acknowledging the Expanding Commercial Success of Cell Therapies** 

Opening Remarks

**Keynote Presentation: Newly Approved Program** 

**Keynote Presentation: BLA-Stage Program** 

**Keynote Presentation: Combatting Autoimmune Disease in the Clinic** 

Morning Break & Networking

Discovery Track	Translation Track	Clinical Development Track	Early-Stage Manufacturing Track	Late -Stage Manufacturing Track	Analytical Development Track	Supply Chain & Clinical Operations Track
Progressing In Vivo Engineering of Cells to Transform Scalability & Reinvent Cost- Efficiency	Curating & Executing an Effective Biomarker Strategy to Predict Patient Response	Boosting Clinical Outcome While Maintaining Risk Benefit Ratio	Evaluating & Implementing Technologies to Augment Process Development	Efficiently Scaling- Out Manufacturing to Increase Production Capacity	Shaping a Robust Analytical Strategy to Master Scale-Up	Streamlining Scale-Up & Managing Competition
Progressing In Vivo Engineering Delivery to Improve Targeting Specificity	Identifying & Defining Effective but Accessible Biomarkers of Response	Administering as Earlier Stage Treatment to Promote Clinical Efficacy & Improve Outcome	Manufacturing Process Development to Allow for Flexibility in Technology Implementation	Expanding Manufacturing Infrastructure to Initiate Scale-Out of Production	Analytical Assay Strategy for Next-Gen CAR-T Product Development Targeting Solid Tumors	Highlighting Labeling Standards to Secure Consistency & Outline
Panel Discussion: Highlighting the Next-Gen Opportunity & Potential for <i>In Vivo</i> Engineered Cell Therapies	Panel Discussion: Considering Best Practice to Uncover Effective Biomarkers for Mechanism of Action & Response to Influence Clinical Outcome	Panel Discussion: Reviewing the Clinical Safety of Cell Therapies to Evaluate Risk Benefit Ratio	Panel Discussion: Incorporating Technologies to Optimize Established Processes & Boost Efficiency	Panel Discussion: Considerations to Ensure Efficient Scale-Up & Scale-Out of Products	Panel Discussion: Approaching CMC & Regulatory Strategy to Support & Facilitate Regulatory Compliance & Submissions	Panel Discussion: Addressing Capacity Management in an Increasingly Competitive Landscape

Lunch Break & Networking



**CONTENTS** 

**REGISTER BY APRIL 26** 

**& SAVE UP** 

TO \$1,500!

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-CONFERENCE DAY

CONFERENCE **DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 





### Conference Day Two - Thursday, September 19



September 17-20, 2024 I Boston, MA

Discovery Track	Translation Track	Clinical Development Track	Early-Stage Manufacturing Track	Late -Stage Manufacturing Track	Analytical Development Track	Supply Chain & Clinical Operations Track
Trailblazing Novel Discovery Platforms to Innovate Cell Therapy	Interpreting Learnings from the Clinic & Wider Industry to Further Advance Translational Efforts	Leveraging Combinations to Potentiate Anti-Tumor Response & Overcome Resistance	Mastering Manufacturing of Complex Engineered Cell Therapy Products	Developing a Strategy & Preparing Early to Meet Commercial Demand & Supply	Benchmarking Rigorous Safety Bioassays to Safeguard Smooth Product Validation	Facilitating Geo- Expansion to Boost Treatment Accessibility
Delving into Genomics to Reinvent Target Discovery & Validation	Applying Clinical Learnings to Supercharge TCR-T Therapies	Creating a Synergistic Combination to Overcome the TME & Boost Efficacy in Solid Tumors	Next-Generation CRISPR Genome- Editing Technology for Manufacturing of Clinical Allogeneic CAR-T Cell Therapies	Implementing Rapid & Robust Manufacturing Processes	Detecting Cellular Impurities to Assure Product Purity	Expanding Internationally: Understanding Trade & Distribution Compliance Requirements
Leveraging Next- Generation Screening to Accelerate & Uncover Effective TCRs	Employing Clinical Learnings in Oncology to Enhance Autoimmune Pipeline Development	Uncovering Resistance Mechanisms to Prevent Relapse	Driving Efficient Manufacturing Using Non- Viral Engineering	Round Table Discussion: Developing a Robust Manufacturing Roadmap to Streamline Operations	Advancing Stability Testing to Promote Long- Term Product Safety & Functionality	Establishing a Decentralized Production Model to Simplify Supply Chain & Clinical Operations

Afternoon Break & Networking

#### Streamlining Regulatory & Commercial Strategy to Facilitate Compliance & Approval

**Outlining Regulatory Strategy to Ensure Compliance & Approval** 

Panel Discussion: From Pivotal to Patients: Paving a Smooth Road to Commercial Approval of Accessible Therapies

**Emily Whitehead Foundation Patient Story** 

**Closing Remarks** 



**REGISTER BY APRIL 26 & SAVE UP** TO \$1,500!

**CONTENTS** 

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

CONFERENCE **DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

> **PARTNER** WITH US



(10)

### Post-Conference Focus Day - Friday, September 20



September 17-20, 2024 I Boston, MA

Tackling Solid Tumors	Automation & Manufacturing Technology
Advancing Armoring Strategies to Boost Persistence & Withstand the Solid Tumor Microenvironment	Automating Manufacturing Processes to Reduce Costs & Transform Efficiency
Panel Discussion: Reviewing Armoring Strategies & Relating to Tumor Characteristics to Identify Areas for Opportunity	Employing End-to-End Automation to Boost Manufacturing Productivity
Affini-T Platform Technologies Enable the Generation of Potent & Tolerable TCR-T Cells	Leveraging Modular Automation to Minimize Error while Maintaining Flexibility
Creating T-Cell Therapies with a Stem-Like Phenotype to Boost Persistence	Panel Discussion: Evaluating Technologies to Boost Productivity, Minimize Error & Reduce Costs

Morning Break & Networking

Benchmarking Methods to Master Effective Solid Tumor Trafficking & Penetration	Harnessing Technology & Instrumentation to Facilitate Scale-Up
Harnessing a Cancer-Specific Target Discovery Engine to Uncover Novel Solid Tumor Antigens	Employing Bioreactors to Produce Large-Scale T-Cell Products
Moving Beyond Conventional CAR: Altering CAR Design to Potentiate Anti-Tumor Effect	Creating Closed Systems for Manufacturing to Improve Therapy Accessibility

Lunch Break & Networking

Harnessing Cell Type to Mediate Solid Tumor Infiltration	Facilitating Technology Implementation to Enable Smooth Integration	
Employing Innate Cells to Promote Infiltration of Solid Tumors	Round Table Discussion: Let's Plug & Play - Streamlining Integration of Automation &	
Engineering TIL to Thrive in Hard-to-Treat Solid Tumors Using CRISPR/Cas9 Gene Editing	Novel Technologies into Manufacturing Processes to Achieve Operational Excellence	

Afternoon Break & Networking

Potentiating Targeting Ability through Novel Combination Approaches	Enabling Analytical Instrumentation & Automation to Aid Comparability & Scale-Up	
Leveraging Viral Immunotherapies to Potentiate CAR-T Response through Combination Therapy	Leveraging Instrumentation to Accelerate Release Testing & Minimize Human Input	
Panel Discussion: Combining Cell Therapies with Synergistic Treatments to Prevent Antigen Escape	Enabling Automated Process Monitoring for Production to Boost Efficiency & Product Quality	
CellPryme is a Novel Agent that Improves Cell Phenotype, Improves Tumor Control & Overcomes Immunosuppressive Tumor Microenvironment	Mediating In-Process Analytics to Optimize Production Efficiency	

End of Focus Days







**REGISTER BY APRIL 26 & SAVE UP** TO \$1,500!

**CONTENTS** 

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

**CONFERENCE DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 


> **PARTNER** WITH US


**REGISTER** NOW


#### **Take the Spotlight - Partner With Us**


**Your Premier Meeting to Connect & Foster** Relationships within the Cell Therapy Industry

#### Why Partner with the 9th CAR-TCR Summit:
















#### **How Will the 9th CAR-TCR Summit Team Support You?**











Luke O'Neill Commercial Manager

Telephone: +1 617 455 4188 | Email: sponsor@hansonwade.com

#### **Lead Partner**

### Lonza

Cell & Gene

#### **Expertise Partners**













#### **Program Partners**







































#### **Hosting Partners**











#### **Exhibition Partners**









































Email: info@hansonwade.com







**REGISTER BY APRIL 26** & SAVE UP TO \$1,500!

**CONTENTS** 

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

**MAP OUT YOUR MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

**CONFERENCE DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 

> **PARTNER** WITH US



NOW

# READY TO REGISTER?

### **Team Discounts**

- 3 Passes 10% Discount
- 4 Passes 15% Discount
- 5+ Passes 20% Discount

Group discounts cannot be used in conjunction with any other discounts (including academic rates). Group discounts can still be applied to early bird savings. For more information on group rates and eligibility criteria, please email info@hansonwade.com or visit the website. Full T&Cs apply.

### **Secure Your Place Now**



September 17-20, 2024 | Boston, MA

INDUSTRY PRICING	Register & Pay By Friday, April 26	Standard Rate
Conference + (Workshop Day OR Bootcamp OR Fundamentals Day) PLUS Focus Day	\$3,895 <b>(Save \$1,500)</b>	\$5,395
Conference + Workshop Day OR Bootcamp Day OR Fundamentals Day OR Focus Day	\$3,097 <b>(Save \$1,100)</b>	\$4,197
Conference Only	\$2,299 (Save \$700)	\$2,999
ACADEMIC & START-UP* PRICING	Register & Pay By Friday, April 26	Standard Rate
ACADEMIC & START-UP* PRICING  Conference + (Workshop Day OR Bootcamp OR Fundamentals Day) PLUS Focus Day		Standard Rate \$4,595
Conference + (Workshop Day OR Bootcamp OR	April 26	

<sup>\*</sup>Must be from a biotech or pharma company that is currently and publicly developing an in-house cell therapy to be eligible for this price

Do you work for a Service/Solution Provider or Vendor? Email us at sponsor@hansonwade.com to enquire about attending



### **Hynes Convention Center**

Hynes Convention Center, 900 Boylston St, Boston, MA 02115 United States

https://www.signatureboston.com/hynes/



3 Easy Ways To Book



www.car-tcr-summit.com/take-part/register



Email: register@hansonwade.com



Tel: +1 617 455 4188

**TERMS & CONDITIONS** 

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A. 6 Honduras Street, London EC1Y 0TH

hansonwade

CONTENTS

**REGISTER BY APRIL 26** 

**& SAVE UP** TO \$1,500!

**WELCOME** 

WHAT'S NEW?

**EXPERT SPEAKERS** 

MAP OUT YOUR **MEETING** 

WHO WILL YOU MEET?

PRE-**CONFERENCE** DAY

**CONFERENCE DAY ONE** 

CONFERENCE **DAY TWO** 

POST-**CONFERENCE FOCUS DAY** 





<sup>\*\*</sup>Must be from a biotech company with less than 50 full-time employees that is currently and publicly developing an in-house cell therapy, or a full time academic to be eligible for this price